<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436475</url>
  </required_header>
  <id_info>
    <org_study_id>DK76092 (completed)</org_study_id>
    <secondary_id>DK76092</secondary_id>
    <nct_id>NCT00436475</nct_id>
  </id_info>
  <brief_title>Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes</brief_title>
  <acronym>CaDDM</acronym>
  <official_title>Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the randomized trial is to quantify the effect of vitamin D and calcium
      supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic
      inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is animal and human observational evidence to suggest that vitamin D and calcium are
      important in modifying t2DM risk but there are critical gaps in our knowledge about the
      clinical magnitude of the association with t2DM and potential mechanisms in humans. We are
      conducting a randomized trial to quantify the effect of vitamin D and calcium supplementation
      on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and
      other cardiometabolic outcomes in ambulatory adults at high risk for t2DM. We anticipate that
      the research proposed in this application is significant because it will provide the basis
      for defining feasible nutritional interventions that promotes prevention of t2DM. Based on
      the results of the proposed studies and future work in this area, vitamin D and calcium
      supplementation can assume an important role in the treatment of t2DM and in the prevention
      of the disease in the 41 million Americans who are at risk of developing t2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity, Insulin secretion, glucose tolerance (fasting, after OGTT), systemic inflammation, lipoprotein profile, blood pressure, body weight and body composition</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic studies on Vitamin D related genes and risk of type 2 diabetes and cardiometabolic outcomes</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To collect and archive biological specimens (serum, plasma, DNA) so that they can be used for testing of new hypotheses either within the parent stud or through future ancillary studies.</measure>
    <time_frame>0 and 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 2,000 IU orally once daily</intervention_name>
    <description>Vitamin D3 2,000 IU orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate 400 mg orally twice daily</intervention_name>
    <description>Calcium Carbonate 400 mg orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3-Placebo</intervention_name>
    <description>Vitamin D3-Placebo</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium-Placebo</intervention_name>
    <description>Calcium-Placebo</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnicity: all ethnic groups

          -  Gender: men and women

          -  Age

               1. Lower age limit: 40 years inclusive

               2. Upper age limit: NONE

          -  BMI

               1. Lower BMI limit: 25 inclusive

               2. Upper BMI limit: 40 inclusive

          -  Glucose Intolerance / Mild Diabetes defined as

               1. Fasting glucose ≥100 mg/dl OR

               2. 2-hr glucose after OGTT ≥140 mg/dl OR

               3. 5.8 ≤ Hemoglobin A1c ≤ 7

        Major Exclusion Criteria:

          -  Diabetes requiring pharmacotherapy

          -  Smoking

          -  Hyperparathyroidism

          -  Hypercalcemia (Calcium &gt; 10.5 mg/dl)

          -  Kidney stone

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastassios G Pittas, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017-29. Epub 2007 Mar 27. Review.</citation>
    <PMID>17389701</PMID>
  </reference>
  <reference>
    <citation>Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007 Apr;30(4):980-6. Epub 2007 Feb 2.</citation>
    <PMID>17277040</PMID>
  </reference>
  <reference>
    <citation>Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006 Mar;29(3):650-6.</citation>
    <PMID>16505521</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Anastassios G. Pittas</name_title>
    <organization>Tufts Medical Center</organization>
  </responsible_party>
  <keyword>Glucose intolerance</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 26, 2016</submitted>
    <returned>November 14, 2016</returned>
    <submitted>December 29, 2016</submitted>
    <returned>February 20, 2017</returned>
    <submitted>March 31, 2017</submitted>
    <returned>May 10, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

